Bone marrow immunophenotyping by flow cytometry in refractory cytopenia of childhood by Aalbers, Anna M et al.
haematologica | 2015; 100(3)
ARTICLES
315
Myelodysplastic Syndromes
Introduction
Myelodysplastic syndrome (MDS) in childhood is rare and
has an annual incidence of 0.8 to 1.8 per million children aged
0 to 14 years.1-3 Refractory cytopenia of childhood (RCC),
defined as myelodysplasia without an increased blast count,
is the most common variant of pediatric MDS. Based on the
2008 WHO criteria,4 a distinction is made between RCC and
the immune-mediated bone marrow (BM) failure syndrome
(very) severe aplastic anemia ((v)SAA), with presence or
absence of patchy erythropoiesis, respectively, as main differ-
entiating parameter.5 Nonetheless, because the majority of
children with RCC have a normal karyotype and 80% of
patients have a hypocellular BM, differentiating RCC from
(v)SAA can be challenging.4,6 Similar challenges are encoun-
tered in distinguishing (v)SAA and other non-clonal cytope-
nias from low-grade MDS in adults, especially in cases with-
out specific morphological or cytogenetic aberrations. Flow
cytometric immunophenotyping is a valuable addition to
morphology in the diagnosis of MDS in adults.7
Abnormalities detected by flow cytometry in myelomono-
cytic, erythroid and/or myeloid blast cells8-17 can be of diag-
nostic and prognostic relevance in adult MDS.18-20 
In pediatric MDS, only a limited number of flow cytometric
immunophenotyping studies have been reported. In
advanced pediatric MDS, CD7 expression on myeloid blast
cells was described to correlate with dismal survival.21 We
recently showed that, in RCC, a simple and reproducible flow
cytometric scoring system, described by Ogata and others as
a diagnostic tool in adult low-grade MDS,15,17 cannot be
applied due to its low sensitivity.22  
In the present study, we performed a comprehensive flow
cytometric analysis of the maturing granulocytic, monocytic,
and erythroid lineages in BM aspirates of 81 RCC patients, col-
lected prospectively by the European Working Group of MDS
in Childhood (EWOG-MDS), and in BM aspirates of healthy
controls, advanced MDS and (v)SAA patients. Our aims were
three-fold. First, to describe the immunophenotypic character-
istics of RCC compared to healthy and pathological controls.
Second, to correlate flow cytometric findings with clinical char-
acteristics of RCC patients. And third, to assess whether flow
cytometry can be of value in differentiating RCC from (v)SAA. 
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Refractory cytopenia of childhood is the most common type of childhood myelodysplastic syndrome. Because the
majority of children with refractory cytopenia have a normal karyotype and a hypocellular bone marrow, differ-
entiating refractory cytopenia from the immune-mediated bone marrow failure syndrome (very) severe aplastic
anemia can be challenging. Flow cytometric immunophenotyping of bone marrow has been shown to be a valu-
able diagnostic tool in differentiating myelodysplastic syndrome from non-clonal cytopenias in adults. Here, we
performed the first comprehensive flow cytometric analysis of immature myeloid, lymphoid cells and erythroid
cells, and granulocytes, monocytes, and lymphoid cells in bone marrow obtained from a large prospective cohort
of 81 children with refractory cytopenia. Children with refractory cyotopenia had a strongly reduced myeloid
compartment, but not as severe as children with aplastic anemia. Furthermore, the number of flow cytometric
abnormalities was significantly higher in children with refractory cytopenia than in healthy controls and in chil-
dren with aplastic anemia, but lower than in advanced myelodysplastic syndrome. We conclude that flow cyto-
metric immunophenotyping could be a relevant addition to histopathology in the diagnosis of refractory cytopenia
of childhood. (The multi-center studies EWOG-MDS RC06 and EWOG-MDS 2006 are registered at clinicaltrials.gov
identifiers 00499070 and 00662090, respectively).
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ABSTRACT
Methods
Patients and controls
BM samples for flow cytometric immunophenotyping were
obtained from 81 primary RCC patients aged 18 years of age or
under, who had not previously been treated with immunosup-
pressive therapy (IST). Consecutive patients, diagnosed between
June 2005 and December 2011, were included from the prospec-
tive, multi-center studies EWOG-MDS RC06 and EWOG-MDS
2006. Institutional review boards of participating institutions
approved the studies and patients and/or parents or legal
guardians of patients provided written informed consent for study
participation in accordance with local laws and regulations. RCC
was diagnosed according to WHO criteria4 and confirmed by cen-
tral review of BM morphology and histology in participating
national study centers by reference pathologists of EWOG-MDS.
BM samples were obtained from 17 pediatric (v)SAA patients
(median age 9.6 years; range 1.6-18.1 years), 7 pediatric patients
with advanced MDS [refractory anemia with excess blasts (RAEB)
or refractory anemia with excess blasts in transformation (RAEB-
t)] (median age 14.3; range 3.9-17.7 years) diagnosed according to
WHO criteria4 by reference pathologists of EWOG-MDS, and
from 9 healthy adult stem cell donors who served as controls. The
histopathological differentiation between RCC and (v)SAA is
mainly based on the presence of patchy erythropoiesis with defec-
tive maturation and/or the presence of micromegakaryocytes in
RCC, and the absence of erythropoiesis and megakaryopoiesis in
(v)SAA.5 It was recently shown that a reproducible distinction
between RCC and (v)SAA can be made based on these criteria.5 In
the RCC cohort, PNH clones and T-cell receptor Vβ skewing were
detected, as described previously.23,24 Further details may be found
in the Online Supplementary Appendix.
Bone marrow immunophenotyping by flow cytometry
BM samples were collected in heparinized tubes, sent to the
Erasmus MC, and generally analyzed within 24 h of collection. A
minimum of 500 mL BM was lysed with NH4Cl, washed, re-sus-
pended in 350 mL PBS/BSA or to a maximum concentration of
20x106 cells/mL, and 50 mL aliquots were stained for 15 min at
room temperature with a monoclonal antibody panel as described
in Online Supplementary Table S1. Cells were acquired on a
FACSCanto II flow cytometer (BD Biosciences), and data were
analyzed using Infinicyt software (Cytognos, Salamanca, Spain) or
BD FACSDiva Software, v.6.1.2 (BD Biosciences). Gating strate-
gies and cell population definitions are described in the Online
Supplementary Appendix.
Parameters that were evaluated in myeloid and lymphoid pro-
genitor cells, maturing granulocytes, monocytes and erythrocytes
are described in Table 1, and are largely in line with European
LeukemiaNet (ELN) recommendations for flow cytometry in
MDS.7 Maturation patterns of the myelomonocytic lineage, and
expression of CD markers on myeloid blast cells, granulocytes and
monocytes were compared with reference images (Infinicyt set-
tings: resolution 128, maximum density increment, linear) that
were generated, depending on the combination of antibodies
used, by merging flow cytometric data from 6-8 normal BM sam-
ples (100,000 events per sample, merged into 100,000 events).
Maturation patterns and expression of CD markers were scored as
aberrant when the expression of the analyzed population deviated
more than 0.5 log decade from the expression of the reference
population. Granularity of myeloid blasts (CD117+), granulocytes
(CD33dim), and monocytes (CD64+) was expressed as the relative
SSC compared to lymphocytes. The relative granularity of
myeloid blasts (CD117+), granulocytes (CD33dim), and monocytes
(CD64+) of individual RCC patients or controls was scored as
abnormal when the relative granularity was less than 2 SD of the
mean of the relative granularity of healthy controls. When less
than 50 myeloid blasts, less than 1000 granulocytes, or less than 50
immature erythroid cells were present, percentages were reported,
but cell populations were not further characterized.
The total number of flow cytometric abnormalities was calcu-
lated by adding up all flow cytometric abnormalities described in
Table 1.
Statistical analyses
Statistical analyses are described in the Online Supplementary
Appendix.
Results
Patients’ characteristics
A total of 81 treatment-naïve RCC patients (40 male, 41
female), with a median age at diagnosis of 10.5 years
(range 1-18 years), were analyzed. Median time from diag-
nosis to analysis was 1.5 months. Clinical characteristics
of the patients included in the study are summarized in
Table 2. Hypocellular BM was reported in 80% of
patients, similar to the previously reported frequency of
81% of primary RCC patients in an interim analysis of
studies EWOG-MDS 1998 and 2006.6 Conventional cyto-
genetics displayed a normal karyotype in 61 of 71 evalu-
able patients (86%, which is slightly higher than the pre-
viously reported frequency of 77%),6 monosomy 7 in 5 of
71 patients (including one patient with monosomy 7 and
additional aberrations) (7%), and other aberrations in 5 of
71 patients (trisomy 8 in 2 patients, rare aberrations in 2
patients, and del(7q) in one patient) (7%). In 9 patients, no
karyotype was obtained due to insufficient metaphases; in
one patient, no information was available.
Cellular composition of RCC versus healthy control
bone marrow
Patients with RCC showed a strong decrease in the
myeloid and lymphoid progenitor compartment com-
pared to healthy controls. The median percentage of
myeloid blast cells (CD117+) was only 0.1% in RCC, com-
pared to 0.9% in controls; similarly, the percentages of
promyelocytes and immature erythroid cells were
decreased. As previously observed in adult MDS
patients,19 the percentage of CD34+ B-cell precursors was
significantly decreased in RCC, with a median percentage
of 0.0% in RCC versus 0.3% in controls (Table 3).
In parallel with a reduction in immature myeloid cells,
the percentage of granulocytes (CD33dim) was strongly
decreased in RCC (median: 27.5% in RCC vs. 60.9% in
controls), with a relative increase in mature CD10+ granu-
locytes in RCC (median: 47.9% in RCC vs. 28.7% in con-
trols). The percentage of monocytes (CD64+) was similar
in RCC patients and controls, although monocytes were
low or absent in some RCC patients (Table 3).
Remarkably, in one RCC patient, 23% of all nucleated
cells were monocytes.
Likely in part due to the reduction in myeloid cells, the
proportion of lymphocytes in RCC was strongly
increased, with a median of 47.7% in RCC versus 11.4%
in controls. The median percentage of T cells was 39% in
RCC and 7.7% in controls. The percentages of NK and
total B cells were also increased in RCC, but the propor-
tion of B-cell precursors was reduced. There was no differ-
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ence in the percentage of basophils in RCC to those of
healthy controls, while the percentage of plasmacytoid
DCs was reduced. Results are summarized in Table 3 and
Figure 1. 
Cellular composition of bone marrow of RCC versus
(v)SAA and RAEB(-t) 
Although the proportions of progenitor and mature
myeloid cells were strongly reduced in RCC patients com-
pared to healthy controls, in (v)SAA this reduction was
even more severe. The median percentage of myeloid
blasts, promyelocytes, and CD34+ B-cell precursors was
0.0% in (v)SAA; the proportion of immature erythroid
cells was 0.8%. The percentage of granulocytes (CD33dim),
already reduced in RCC compared to healthy controls,
was further decreased in (v)SAA (median 9.1%) compared
to RCC, as was the percentage of monocytes (CD64+).
The proportion of lymphocytes was strongly increased in
(v)SAA compared to RCC, with a median of 71.9%, while
the percentage of T cells was similar in (v)SAA and RCC.
Percentages of B and NK cells were higher in (v)SAA,
while basophils and plasmacytoid DCs were reduced in
(v)SAA compared to RCC (Table 3). 
Not unexpectedly, compared to patients with RCC,
pediatric patients with RAEB(-t) had  increased percent-
ages of myeloid blasts (CD117+), promyelocytes, and ery-
throid cells, while the percentage of CD34+ B-cell precur-
sors, granulocytes and monocytes were equally low. The
proportion of lymphocytes, T, NK, and B cells were lower
in RAEB(-t) than in RCC patients; the percentages of
basophils and plasmacytoid DCs were similar. Results are
summarized in Table 3 and Figure 1. A graphic presenta-
tion of the BM cellular composition of RCC patients and
controls is provided in Online Supplementary Figure S1. 
Immunophenotype of myeloid blast cells in RCC 
and controls
In adult MDS patients, the granularity of myeloid blast
cells is frequently decreased, and lineage infidelity markers
are often detected.19 In our RCC series, the granularity of
Bone marrow immunophenotyping in RCC
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Table 1. Analyzed parameters per cell population.
Myeloid and lymphoid progenitors Erythrocytes Granulocytes Monocytes Other cells
Percentage of CD34+ Percentage of Percentage of Percentage of Percentage of
B-cell precursors erythroid cells granulocytes monocytes (CD64+) lymphocytes
(CD235+ and/or CD71+) (CD33dim)
Percentage of myeloid Heterogeneous Percentage of SSC Percentage of T cells
blasts (CD34+/CD117+) expression of CD71 CD10+ and CD10– monocyte/lymphocyte
granulocytes
Percentage of Heterogeneous SSC Abnormal expression Percentage of NK cells
promyelocytes (CD34–/ expression of CD36 granulocyte/lymphocyte of CD13
CD117+/CD13.33+)
SSC myeloid blast/lymphocyte Abnormal CD11b-CD13 Abnormal expression of Percentage of B cells
pattern CD14
Abnormal expression of  CD11b Abnormal CD16-CD13 Abnormal expression of Percentage of mature 
pattern CD36 B cells (CD19+/CD10–)
Abnormal expression of CD117 Abnormal expression Abnormal expression Percentage of B-cell
of CD33 of CD33 precursors
(CD19+/CD10+)
Abnormal expression of CD34 Expression of CD34 Abnormal HLA-DR-CD11b Percentage of basophils
pattern
Expression of CD15 Abnormal expression of CD15 Expression of CD34 Percentage of
plasmacytoid DCs
Expression of CD64 Abnormal expression of CD64  Abnormal expression of CD15
Abnormal expression of HLA-DR Expression of HLA-DR Abnormal expression of CD64
Expression of CD7 Abnormal expression of HLA-DR
Expression of CD56 Expression of CD56
Table 2. Clinical and laboratory characteristics of refractory cytopenia
of childhood patients included in the study.
Characteristic                                                                          
N. of patients                                                                                          81
Median age at diagnosis, years (range)                                  10.5 (1-18)
Male sex, n. (%)                                                                               40 (49)
Hypocellular bone marrow, n. (%)                                          64 of 80 (80)
Cytogenetics, n. (%)*                                                                            
Normal                                                                                           61 of 71 (86)
Monosomy 7°                                                                                 5 of 71 (7)
Other#                                                                                               5 of 71 (7)
Blood counts at diagnosis, median (range) (n.)                             
Leukocyte count, x109/L                                                         2.8 (0.8-10.3) (77)
ANC, x 109/L                                                                             0.6 (0.016-5.7) (73)
Hb, g/dL                                                                                     8.9 (3.2-13.8) (77)
MCV >97th percentile for age, n. (%)                                     52 of 74 (70)
Platelet count, x109/L                                                                33 (1-430) (77)
Transfusion dependency at diagnosis, n. (%)                                  
Platelets, n. (%)                                                                           11 of 72 (15)
Erythrocytes, n (%)                                                                     8 of 72 (11)
*In 9 of 80 patients (11%) no karyotype was obtained due to insufficient metaphases;
in 1 patient, no data were available. °Includes 1 patient with monosomy 7 and other
aberrations. #Includes 1 patient with del(7q), 2 patients with trisomy 8, and 2 patients
with rare aberrations.
myeloid blast cells (CD117+), expressed as ratio to the SSC
of lymphocytes, was slightly increased compared to
healthy controls, but did not differ from that of (v)SAA
patients (median 2.15, 1.76, and 2, respectively; P=0.000
and P=NS). A decreased granularity (less than 2 SD of the
mean of healthy controls) was observed in only one of 45
RCC patients with sufficient evaluable myeloid blast cells
(CD117+) and none of the 2 evaluable (v)SAA patients.
Expression of the lineage infidelity marker CD7 on
myeloid blast cells was detected in 6 of 45 evaluable RCC
patients (13%), and in none of the healthy controls or
(v)SAA patients; expression of CD56 was also detected in
6 of 45 RCC patients, and in none of the healthy controls
or (v)SAA patients. In RAEB(-t) patients, multiple abnor-
malities were detected in myeloid blast cells (Table 4). 
Immunophenotype of erythroid cells in RCC 
and controls
The most frequently observed abnormality in immature
erythroid cells in RCC was heterogeneous expression of
CD71 (transferrin receptor) and CD36 (thrombospondin
receptor), which was detected in 42 of 72 RCC patients
(58%) with evaluable erythroid cells (Figure 2A-C). In
healthy controls, one patient showed heterogeneous
expression of CD36; 2 of 11 evaluable (v)SAA patients
(18%) and 3 of 7 RAEB(-t) patients (43%) showed hetero-
geneous expression of CD36 and CD71 (Table 4). In the
RCC, (v)SAA, and RAEB(-t) patients with heterogeneous
expression of CD71 and CD36, this always co-occurred. 
Immunophenotype of granulocytes in RCC and controls  
No significant differences in the relative SSC of granulo-
cytes (CD33dim) were observed between RCC and healthy
controls, or between RCC and (v)SAA patients (data not
shown). However, of the 75 RCC patients with sufficient
granulocytes (CD33dim) for reliable evaluation, 6 (8%) had
a relative SSC that was below the normal range (mean +/-
2SD) of the relative SSC in healthy controls. Such low rel-
ative SSC was also observed in 3 out of 13 evaluable
(v)SAA patients (23%) but in none of the healthy controls.
An abnormal pattern of CD16 and CD13 expression on
maturing granulocytes was detected in 14% of evaluable
RCC patients, comparable to 15% detected in (v)SAA;
none of the healthy controls showed an abnormal CD16-
CD13 pattern (Figure 2D-F). Of note, the mere absence of
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Figure 1. Cellular composition of bone marrow in refractory cytope-
nia of childhood patients and controls. For graphical representation,
means of the main cell populations were calculated per patient and
control group, and scaled to 100%. Precursors consist of myeloid
blast cells and CD34+ B-cell precursors. NBM: normal bone marrow.
Figure 2. Immunophenotype of
immature erythroid cell, granulo-
cytes, and monocytes in refractory
cytopenia of childhood patients
and controls. (A) Normal expres-
sion of CD71 in healthy control
bone marrow, ID NBM 023. 
(B) Heterogeneous CD71 expres-
sion in RCC patient, ID CH028. 
(C) Heterogeneous CD71 expres-
sion in RCC patient, ID I 220. 
(D) Normal pattern of CD16-CD13
expression in healthy control bone
marrow, ID NBM 023. 
(E) Abnormal pattern of CD16-
CD13 expression in RCC patient,
ID D 663. (F) Abnormal pattern of
CD16-CD13 expression in RCC
patient, ID D 555. (G) Absence or
low level of CD56 expression on
monocytes, indicated in orange, in
healthy control bone marrow, ID
NBM 023. Granulocytes and lym-
phocytes are indicated in pink and
green, respectively. (H) Aberrant
expression (>20%) of CD56 on
monocytes in RCC patient, ID
CZ078. (I) Aberrant expression
(>20%) of CD56 on monocytes in
RCC patient, ID SC126. Pink and
orange lines indicate reference
image of normal granulocytes and
monocytes, respectively.
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a granulocyte subset was not considered an abnormal pat-
tern. Less frequently occurring abnormalities in RCC and
(v)SAA, and abnormalities detected in RAEB(-t) patients
are described in Table 4. 
Immunophenotype of monocytes in RCC and controls 
The relative SSC of monocytes (CD64+) in RCC was
increased compared to healthy controls, but did not differ
from (v)SAA patients (median 3.1, 2.8, and 3, respectively;
P=0.006 and P=NS). Three of 74 RCC patients (4%) with
sufficient cells to evaluate, none of the 13 evaluable
(v)SAA patients, and one healthy control had a decreased
granularity. Expression of CD56 on more than 20% of
monocytes occurred in 15 of 74 RCC patients (20%), and
in none of the healthy controls and (v)SAA patients (Figure
2G-I). Abnormalities detected in RCC patients and con-
trols, including RAEB(-t), are described in Table 4. 
Total number of flow cytometric abnormalities in RCC
compared to controls
Of the 81 RCC patients, 57 (70%) displayed one or
more flow cytometric abnormalities, and 49 (60%) two or
more. In one healthy control BM sample, flow cytometric
abnormalities were present. This control sample displayed
a decreased granularity of the monocytes, and heteroge-
neous expression of CD71 on immature erythroid cells. Of
the (v)SAA patients, 6 of 17 (35%) had one or more, and 2
of 17 (12%) had two or more abnormalities. In the RAEB(-
t) group, all patients displayed two or more abnormalities.
Using a cutoff of 2 abnormalities, flow cytometry has a
sensitivity for the recognition of RCC of 60%, and a speci-
ficity, using (v)SAA patients as control group, of 88%. 
The median number of abnormalities was 2 (range 0-6)
in the RCC patients, which is higher than the number of
abnormalities in healthy control BM (median 0, range 0-
2; P=0.0018), and higher than in the (v)SAA patients
(median 0, range 0-3; P=0.0012), but lower than in RAEB(-
t) patients (median 4, range 2-9; P=0.0017) (Figure 3). 
It is worthy of note that one patient with MDS-RAEB
had no detectable CD34+ B-cell precursors, very few
CD19+/CD10+ B-cell precursors and NK cells, a large pro-
portion of large granular lymphocyte-type cells
(CD3+CD16.56+), no monocytes, and an increased per-
centage of myeloid blast cells, that were phenotypically
normal. Granulocytes showed an abnormal CD11b-CD13
and CD16-CD13 expression (Online Supplementary Figure
S2). This immunophenotype was previously described in
patients with the autosomal dominant and sporadic
monocytopenia and mycobacterial infection (MonoMAC)
Bone marrow immunophenotyping in RCC
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Table 3. Bone marrow cellular composition in refractory cytopenia of childhood patients and controls.
NBM RCC (v)SAA RAEB(-t) RCC versus
(n=9) (n=81) (n=17) (n=7) NBM (v)SAA RAEB(-t)
Cell population (%) median (range) median (range) median (range) median (range) P P P
Myeloid and lymphoid progenitors
Myeloid blasts (CD117+) 0.9 (0.8-1.2) 0.1 (0-2.1) 0.0 (0.0-0.3) 8.9 (1-31.9) 0.000 0.000 0.000
CD34+ B-cell precursors 0.3 (0.1-0.8) 0.0 (0.0-4.6) 0.0 (0.0-0.1) 0.0 (0.0-1.4) 0.000 0.008 NS
Promyelocytes 2.1 (0.7-2.7) 0.1 (0.0-2.8) 0.0 (0.0-0.3) 1.6 (0.0-5.4) 0.000 0.001 0.002
Erythroid cells
Erythroid cells 9.8 (4.2-15.6) 3.4 (0.0-43.1) 0.8 (0.0-10.1) 7.9 (2.3-23.8) 0.001 0.004 0.035
Myeloid cells
Granulocytes (CD33dim)* 60.9 (57.4-68.5) 27.5 (0.0-73.5) 9.1 (0.0-62.4) 39.7 (7.6-68.4) 0.000 0.035 NS
CD10– granulocytes° 66.8 (40.8-78) 52.1 (3.1-88) 50.7 (20.3-87.4) 62.5 (44.2-96.3) 0.047 NS 0.097
CD10+ granulocytes° 28.7 (18.9-49.6) 47.9 (12-96.9) 48.2 (12.2-79.8) 36.2 (3.7-53) 0.002 NS 0.069
Monocytes (CD64+) 3.2 (2.8-5.1) 3.4 (0.0-22.8) 1.5 (0.0-6.1) 4.3 (0.0-24.8) NS 0.025 NS
Lymphoid* and other cells
Lymphocytes 11.4 (5.8-13.1) 47.7 (4.5-97.9) 71.9 (21.2-96.2) 18.7 (8.9-64.3) 0.000 0.021 0.017
B cells 3.1 (1.3-7.3) 6.3 (0.2-24.4) 13.1 (5.3-42.7) 3.6 (1.6-11.8) 0.017 0.000 0.031
Mature B cells, CD19+/CD10– 2.0 (0.9-3) 5.1 (0.2-21.7) 13.1 (3.1-42.7) 3.3 (1.0-5.5) 0.001 0.000 0.037
B-cell precursors, CD19+/CD10+ 1.3 (0.4-4.3) 0.3 (0-21.5) 0.1 (0.0-4.5) 0.2 (0.0-6.3) 0.012 NS NS
T cells 7.7 (4.2-9.5) 39 (2.3-86.2) 49.5 (14.1-85.3) 11.3 (6.9-63.5) 0.000 NS 0.030
NK cells 1.1 (0.2-2.4) 2.7 (0.2-11.7) 3.9 (1.6-10.2) 0.9 (0.2-2.2) 0.009 0.016 0.005
Basophils 0.2 (0.0-0.3) 0.1 (0.0-1.0) 0.0 (0.0-0.8) 0.0 (0.0-1.3) 0.093 0.007 NS
Plasmacytoid DCs 0.3 (0.3-0.4) 0.2 (0.0-1.1) 0.0 (0.0-0.4) 0.3 (0.0-1.5) 0.001 0.005 NS
*Evaluated in 80 RCC patients; no data in 1 patient. °Evaluated in 75 RCC patients, 13 (v)SAA patients, and 6 RAEB/RAEB-t patients due to absence of sufficient granulocytes in
remaining patients. NBM: normal bone marrow. 
Figure 3. Number of flow cytometric abnormalities in refractory
cytopenia of childhood patients and controls. Lines indicate medi-
ans. Boxes extend from the 25th to 75th percentile; lines in the boxes
indicate medians, whiskers indicate minimum and maximum val-
ues. **P<0.01; ****P<0.0001. NBM: normal bone marrow.
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syndrome who developed MDS,25,26 in whom germ-line
mutations in GATA2 were later identified.27-31 Indeed, in
the present MDS-RAEB patient, a GATA2 mutation was
detected. 
Flow cytometric abnormalities and clinical 
characteristics in RCC
No significant associations were detected between the
presence of flow cytometric abnormalities (defined as 2 or
more abnormalities) in RCC patients and age or sex, the
presence of human leukocyte antigen (HLA)-DR15 (found
in an increased frequency in adult low-grade MDS and
aplastic anemia patients32,33 and associated with a better
response to IST34), BM cellularity, transfusion dependency
at diagnosis, the presence of a PNH clone, or skewing of
the T-cell receptor Vβ chain (data not shown). Interestly,
however, all 5 RCC patients carrying the cytogenetic
abnormality monosomy 7, associated with a high risk of
progression to AML, had at least two immunophenotypic
abnormalities. Heterogeneous expression of CD71 and
CD36 on erythroid cells, also the most frequently occur-
ring abnormality in the total RCC cohort, was present in 4
of 5 patients carrying monosomy 7; the other abnormali-
ties were non-recurrent or recurrent in only 2 of 5 patients
(Online Supplementary Table S2). No relation was detected
between the presence of flow cytometric abnormalities
and white blood cell count, absolute neutrophil count,
hemoglobin level, MCV, or thrombocyte count (data not
shown). Only 22 RCC patients with a hypocellular bone
marrow included in this study were treated with IST. In
this limited number of patients, no significant association
was observed between the presence of flow cytometric
abnormalities and IST response (data not shown).
Combination of cytopenia and flow cytometric 
abnormalities to identify RCC and (v)SAA patients
In the majority of RCC patients, immature myeloid
and/or lymphoid cells were reduced in numbers, but still
detectable, while in the vast majority of (v)SAA patients,
myeloid blast cells and CD34+ B-cell precursors were
absent: both cell types were absent in 27 of 81 RCC
patients (33%) and in 15 of 17 (v)SAA patients (88%). Two
or more immunophenotypic abnormalities were detected
in 49 of 81 RCC patients (60%), and in 2 of 17 (v)SAA
patients (12%). If a diagnosis of RCC was considered
when myeloid blast cells and/or CD34+ B-cell precursors
A.M. Aalbers et al.
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Table 4. Flow cytometric abnormalities in refractory cytopenia of childhood patients and controls.
Flow cytometric abnormality NBM RCC (v)SAA RAEB(-t)
Myeloid blast cells, n. (%)
Abnormal granularity 0 of 7 (0) 1 of 45 (2) 0 of 2 (0) 3 of 7 (43)
Abnormal expression of CD34 0 of 7 (0) 0 of 45 (0) 0 of 2 (0) 2 of 7 (29)
Abnormal expression of CD117 0 of 7 (0) 1 of 45 (2) 0 of 2 (0) 2 of 7 (29)
Abnormal expression of CD11b 0 of 7 (0) 0 of 45 (0) 0 of 2 (0) 0 of 7 (0)
Abnormal expression of HLA-DR 0 of 7 (0) 0 of 45 (0) 0 of 2 (0) 1 of 7 (14)
Expression of CD64 0 of 7 (0) 0 of 45 (0) 0 of 2 (0) 0 of 7 (0)
Expression of CD15 0 of 7 (0) 0 of 45 (0) 0 of 2 (0) 0 of 7 (0)
Expression of CD7 >20% 0 of 9 (0) 6 of 45 (13) 0 of 2 (0) 2 of 7 (29)
Expression of CD56 >20% 0 of 9 (0) 6 of 45 (13) 0 of 2 (0) 0 of 7 (0)
Erythroid cells, n. (%)
Heterogeneous expression of CD71 1 of 9 (11) 42 of 72 (58) 2 of 11 (18) 3 of 7 (43)
Heterogeneous expression of CD36 0 of 9 (0) 42 of 72 (58) 2 of 11 (18) 3 of 7 (43)
Granulocytes, n. (%)
Abnormal granularity 0 of 9 (0) 6 of 75 (8) 3 of 13 (23) 1 of 7 (14)
Decreased myeloid/lymphoid ratio1 0 of 9 (0) 52 of 81 (64) 13 of 17 (76) 1 of 7 (14)
Expression of HLA-DR 0 of 7 (0) 2 of 75 (3) 0 of 13 (0) 1 of 7 (14)
Abnormal expression of CD64 0 of 7 (0) 0 of 75 (0) 0 of 13 (0) 0 of 7 (0)
Abnormal expression of CD15 0 of 7 (0) 0 of 75 (0) 0 of 13 (0) 0 of 7 (0)
Expression of CD34 0 of 7 (0) 0 of 75 (0) 0 of 13 (0) 0 of 7 (0)
Abnormal expression of CD332 0 of 9 (0) 0 of 75 (0) 0 of 13 (0) 2 of 7 (29)
Abnormal CD11b-CD13 pattern3 0 of 9 (0) 4 of 74 (5) 0 of 13 (0) 3 of 7 (43)
Abnormal CD16-CD13 pattern4 0 of 9 (0) 10 of 73 (14) 2 of 13 (15) 5 of 7 (71)
Monocytes, n. (%)
Abnormal granularity 1 of 7 (14) 3 of 74 (4) 0 of 13 (0) 3 of 6 (50)
Abnormal expression of HLA-DR 0 of 7 (0) 0 of 74 (0) 0 of 13 (0) 0 of 6 (0)
Abnormal expression of CD64 0 of 7 (0) 0 of 74 (0) 0 of 13 (0) 0 of 6 (0)
Abnormal expression of CD15 0 of 7 (0) 0 of 74 (0) 0 of 13 (0) 1 of 6 (17)
Expression of CD34 0 of 7 (0) 0 of 74 (0) 0 of 13 (0) 1 of 6 (17)  
Abnormal HLA-DR-CD11b pattern 0 of 7 (0) 0 of 74 (0) 0 of 13 (0) 0 of 6 (0)
Abnormal expression of CD332 0 of 9 (0) 3 of 74 (4) 0 of 13 (0) 0 of 6 (0)
Abnormal expression of CD14 0 of 9 (0) 0 of 74 (0) 0 of 13 (0) 0 of 6 (0)
Abnormal expression of CD36 0 of 9 (0) 0 of 74 (0) 0 of 13 (0) 2 of 6 (33)
Abnormal expression of CD135 0 of 9 (0) 3 of 72 (4) 0 of 13 (0) 0 of 4 (0)
Expression of CD56 >20% 0 of 9 (0) 15 of 74 (20) 0 of 13 (0) 0 of 6 (0)
1A decreased myeloid/lymphoid ratio was not counted as flow cytometric abnormality in the final sum of abnormalities. 2When both granulocytes and monocytes had a decreased
expression of CD33, this was not considered abnormal. 3No data available in one RCC patient. 4In one RCC patient, a PNH clone in the granulocytic lineage of 86% was present; no
data available in another RCC patient. 5In one RCC patient, insufficient monocytes for reliable analysis were present in this labeling; no data available in one RCC patient. In 2 RAEB
patients, monocytes could not be reliably gated based on SSC and CD45 expression. NBM: normal bone marrow. 
were present, or if two or more immunophenotypic
abnormalities were detected, 61 of 81 RCC patients (84%)
could be correctly classified, whereas the specificity of this
combination, using (v)SAA as a control group, was 76%
(13 of 17 (v)SAA patients) (using conventional diagnostics
including histopathology as the gold standard). The posi-
tive and negative predictive values were 94% (68 of 72
patients) and 50% (13 of 26 patients), respectively.  In 55
RCC patients with a hypocellular BM, and a normal kary-
otype or insufficient metaphases to obtain a karyotype, 45
patients were correctly identified by flow cytometry as
RCC, resulting in a sensitivity of the combined score in
this group of patients of 82%.
Discussion
Flow cytometric immunophenotyping has been shown
to be of value in distinguishing MDS from non-clonal
cytopenias in adult patients.7 In the present study, we eval-
uated whether flow cytometry can help distinguish RCC
from healthy controls, and from (v)SAA and advanced
MDS. We analyzed percentages and/or dysplastic features
of the immature myeloid and lymphoid, immature ery-
throid, maturing granulocytic, monocytic and lymphocyte
compartments.
In RCC, the myeloid compartment, both mature and
immature, appeared severely compromised in comparison
to healthy controls. This finding is not unexpected
because BM is hypocellular in the majority of RCC cases.
In comparison with (v)SAA, however, the reduction in
myeloid cells was less severe in RCC, similar to what has
been shown previously by Reiterova and others, although
in a smaller cohort of pediatric RCC and (v)SAA patients.35
An important difference was the complete absence of
myeloid blast cells and CD34+ B-cell precursors in the
majority of (v)SAA patients, while in most RCC patients
some progenitor cells were still detectable. Interestingly, in
5 pediatric patients with other cytopenias than RCC or
(v)SAA (3 with Fanconi anemia, one with transient ery-
throblastopenia of childhood, one with immune thrombo-
cytopenic purpura), the percentages of CD34+ B-cell pre-
cursors, myeloid blast cells, and promyelocytes were sig-
nificantly higher than in RCC (data not shown). We com-
pared the BM composition of pediatric patients with
healthy adult controls because healthy pediatric controls
are rarely available. In comparison with healthy pediatric
controls, the reduction in myeloid blast cells and CD34+ B-
cell precursors in RCC patients would probably be even
more severe because the precursor compartment in chil-
dren is relatively larger than in adults.22,36
In comparison with studies in adult low-grade MDS, we
detected relatively few flow cytometric abnormalities in
RCC, apart from the severe reduction of myeloid cells.
Furthermore, there was a difference in the type of
immunophenotypic abnormalities between RCC and
adult low-grade MDS. One of the commonly occurring
abnormalities in adult MDS is an abnormally decreased
SSC of granulocytes, which is reflective of hypogranulari-
ty. The relative SSC of granulocytes in RCC did not differ
from that of healthy controls or (v)SAA patients.
Expression of lineage infidelity markers on myeloid blast
cells, another common finding in adult MDS, was also not
observed frequently in RCC. In adult MDS, lineage infi-
delity marker expression correlates with an increased blast
percentage and a more advanced disease stage.19,37 That
RCC is a low-grade MDS subtype may partly explain the
low frequency of lineage infidelity marker expression on
myeloid blast cells. In RCC, the most frequently occurring
immunophenotypic abnormality was heterogeneous
expression of CD71 and CD36 on erythrocytes in 58% of
cases (see below), followed by aberrant expression of CD56
on monocytes in 20% of cases, which might reflect
stressed hematopoiesis rather than true dysplasia. All
other abnormalities occurred in a lower frequency in RCC.
Of interest, although only 5 patients with monosomy 7
were included in the present study, all of them displayed
at least 2 flow cytometric abnormalities. RCC with mono-
somy 7 confers a high risk of progression to acute myeloid
leukemia, but histopathologically no differences can be
detected between RCC cases with or without monosomy
7.6 A possible explanation for this difference might be that
flow cytometry can detect subtle dysplastic changes with
a greater sensitivity than histopathology, partly because
more cells can be examined by flow cytometry (generally
≥100,000 cells) than by morphology (generally ≤500 cells).
The histopathological differentiation between RCC and
(v)SAA is mainly based on the presence of patchy erythro-
poiesis with defective maturation and/or the presence of
micromegakaryocytes in RCC, and the absence of ery-
thropoiesis and megakaryopoiesis in (v)SAA.5 These
histopathological differences are reflected by the differ-
ences we detected by flow cytometry between RCC and
(v)SAA. In our flow cytometric analyses, the percentage of
immature erythroid cells in RCC was higher than in
(v)SAA patients. Furthermore, we detected heterogeneous
expression of CD71 and CD36 in a large proportion of
RCC patients. The exact meaning of this heterogeneous
expression is unclear, but flow cytometric abnormalities in
CD71 and/or CD36 expression on immature erythroid
cells are specific and recurrent findings in adult MDS
patients.8,10,11,38-40 Flow cytometric evaluation of megakary-
opoieis still has its limitations, but it was recently shown
that abnormalities detected in peripheral blood platelets
by flow cytometry are of diagnostic significance in adult
MDS.41 Future studies will be needed to reveal whether
immunophenotyping of platelets and/or megakaryocytes
can be of additional value in distinguishing RCC from
(v)SAA as well. Apart from flow cytometric immunophe-
notyping, deep-sequencing approaches, which have now
become readily available, but have not yet been systemat-
ically applied in RCC and (v)SAA, might be of value in
identifying differences between the two groups.
Distinguishing RCC from (v)SAA remains of clinical rel-
evance, even though the pathophysiology of RCC seems,
similar to (v)SAA, at least in part immune-mediated, also
given the good response in selected RCC patients to
IST.23,42 The rate of clonal evolution after IST in RCC
patients, ranging from 4% to 14% (in rabbit and horse
ATG, respectively),42 might be higher than in (v)SAA
patients, in whom the probability of clonal evolution had
dropped to 3% in a recent interim analysis (type of ATG
not reported).5 Furthermore, while the conditioning regi-
men before hematopoietic stem cell transplantation is
myeloablative (reduced intensity in selected patients) in
RCC, this is not the case in (v)SAA patients.43,44 
One of the limitations of this study is the possibility of
peripheral blood contamination of BM aspirates. Future
studies might choose to determine the purity of BM or to
correct for peripheral blood contamination by methods that
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have been described previously.45-47 A certain degree of
peripheral blood contamination seems unavoidable given
the hypocellularity of BM in the majority of RCC patients.
Another limitation of our study and of most other studies
evaluating the value of flow cytometry as a diagnostic tool
in MDS, is that, although determining cell numbers by flow
cytometry is fairly objective, scoring of dysplasia remains
subjective. Therefore, future studies assessing the value of
flow cytometry as a means to differentiate RCC from non-
clonal cytopenias should employ more standardized proto-
cols and antibody panels, and novel software tools that
might be able to more objectively evaluate myeloid dyspla-
sia.48,49 When our results can be reproduced in an independ-
ent cohort of RCC and (v)SAA patients, flow cytometric
immunophenotyping could be included in the diagnostic
workup of childhood cytopenias also in laboratories with a
more limited expertise in flow cytometry. 
In summary, RCC patients have a strongly reduced
myeloid compartment in comparison to healthy controls,
but the reduction is not as severe as in (v)SAA patients. We
also report that the number of abnormalities detected by
flow cytometry is significantly higher in RCC patients
than in healthy controls and in pediatric patients with
(v)SAA, but lower than in advanced MDS. Our results
indicate that, although flow cytometric abnormalities in
RCC patients are present at a relatively low frequency,
flow cytometric immunophenotyping might be a relevant
addition to histopathology and cytogenetic analysis in the
diagnosis of RCC. Particularly the combined use of cellular
composition and flow cytometric abnormalities may sup-
port the distinction between RCC and SAA with good
specificity (84%) and sensitivity (76%).
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